Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone202-734-3400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$165.08 million
Profitability
Miscellaneous
Employees273
OptionableOptionable
Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.18. The biopharmaceutical company earned $49.13 million during the quarter, compared to the consensus estimate of $49.44 million. Vanda Pharmaceuticals had a return on equity of 5.88% and a net margin of 7.06%. Vanda Pharmaceuticals's revenue was up 18.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.03) EPS. View Vanda Pharmaceuticals' Earnings History.
When is Vanda Pharmaceuticals' next earnings date?
What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?
Vanda Pharmaceuticals updated its FY 2018 earnings guidance on Wednesday, November, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180-200 million, compared to the consensus revenue estimate of $192.44 million.
What price target have analysts set for VNDA?
9 Wall Street analysts have issued 1 year price targets for Vanda Pharmaceuticals' stock. Their forecasts range from $26.00 to $52.00. On average, they expect Vanda Pharmaceuticals' share price to reach $40.1429 in the next year. This suggests a possible upside of 29.3% from the stock's current price. View Analyst Price Targets for Vanda Pharmaceuticals.
What is the consensus analysts' recommendation for Vanda Pharmaceuticals?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vanda Pharmaceuticals.
What are Wall Street analysts saying about Vanda Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vanda Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ". We are upgrading and increasing our 12-month PT to $43 from $26. Vanda announced that tradipitant met the primary endpoint in its P2 study in patients with idiopathic and diabetic gastroparesis. Based on our recent KOL due diligence, we are impressed with the effect size magnitude, which points to a clinically meaningful increase in nausea-free days, indicating a clear improvement in patient QoL. Importantly, subgroup analysis of pts experiencing both nausea and vomiting at baseline (n=101) shows that tradi’ met the primary endpoint of change in nausea score (p=0.00002) as well as the number of nausea-free days (p=0.0003), a tough putt" result." (12/4/2018)
- 2. According to Zacks Investment Research, "Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics & genomics, to inform our drug discovery, our clinical trials, and our commercial positioning of our compounds. The Company has three product candidates in clinical development. It's lead product candidate, iloperidone, is a compound for the treatment of schizophrenia & bipolar disorder & is in a Phase III clinical trial for schizophrenia. It's second product candidate, is a compound for the treatment of insomnia & depression which is currently in a Phase III clinical trial for insomnia. It's third product candidate, is a compound for the treatment of excessive sleepiness & is ready for a Phase II clinical trial. " (11/17/2018)
- 3. Stifel Nicolaus analysts commented, "We reiterate our Buy rating and $30 target price. All relevant disclosures and certifications appear on pages 3 – 5 of this report. Stifel does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.Investment Thesis We believe Vanda’s current valuation is an attractive entry point for investors, given its accelerating base business and relatively de-risked, late-stage pipeline that we believe is under-appreciated." (10/31/2018)
Has Vanda Pharmaceuticals been receiving favorable news coverage?
News headlines about VNDA stock have trended extremely positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 4.1 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), Catalent (CTLT), United Therapeutics (UTHR), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), TESARO (TSRO), Array Biopharma (ARRY), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), Horizon Pharma (HZNP) and Intercept Pharmaceuticals (ICPT).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 59)
- Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 53)
- Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 50)
- Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 53)
- Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec.
Who are Vanda Pharmaceuticals' major shareholders?
Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Louisiana State Employees Retirement System (0.04%) and Meeder Asset Management Inc. (0.02%). Company insiders that own Vanda Pharmaceuticals stock include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Which major investors are selling Vanda Pharmaceuticals stock?
VNDA stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and Meeder Asset Management Inc.. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.
How do I buy shares of Vanda Pharmaceuticals?
Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of VNDA stock can currently be purchased for approximately $31.05.
How big of a company is Vanda Pharmaceuticals?
Vanda Pharmaceuticals has a market capitalization of $1.63 billion and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.
What is Vanda Pharmaceuticals' official website?
How can I contact Vanda Pharmaceuticals?
Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]
MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
